|
|
|
|
|
|
|
13.05.26 - 09:03
|
Cepheid Receives CE Marking Under IVDR for Xpert® GI Panel (PR Newswire)
|
|
|
IVDR-compliant PCR test supports detection of 11 clinically relevant gastrointestinal pathogens from 1 sample SUNNYVALE, Calif., May 13, 2026 /PRNewswire/ -- Cepheid, a Danaher company, announced today that it has received CE marking under the in vitro medical device regulation (IVDR) for......
|
|
|
13.05.26 - 08:57
|
Novo Nordisk Hold (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Novo Nordisk auf "Hold" mit einem Kursziel von 270 dänischen Kronen belassen. Beim Pharmakonzern gebe es "so viele Fragen, aber nur wenige Antworten", schrieb Michael Leuchten ......
|
|
|
13.05.26 - 08:54
|
Bayer Aktie: Wieder aufwärts? Chartanalyse (Aktiencheck)
|
|
|
Zürich (www.aktiencheck.de) - Bayer-Chartanalyse der UBS:
Die Aktie der Bayer AG (ISIN: DE000BAY0017, WKN: BAY001, Ticker-Symbol: BAYN, NASDAQ OTC-Symbol: BAYZF) hat gestern mit Kursgewinnen von 3,7% auf die Veröffentlichung der Quartalszahlen reagiert, wie aus der Veröffentlichung "KeyInvest DailyTrader" der UBS hervorgeht. [mehr]...
|
|
|
|
|
13.05.26 - 08:42
|
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results (Business Wire)
|
|
|
FY2025 Pipeline Successes Set the Stage for Pivotal Product Launches
Achieved Latest FY2025 Management Guidance
Takeda is Entering a New Era & Transforming for Growth Acceleration
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management Guidance, reflecting strong OPEX savings, mitigating revenue headwinds while continuing to invest in future growth.
Key Highlights for FY2025
Revenue decreased by 1.7% YoY at actual exchange rates (AER), resulting from the loss of exclusivity for VYVANSE® which was partially mitigated by Growth and Launch Products. On a Core basis, Revenue decreased by 2.6% at Constant Exchange Rate (CER).
Core Operating Profit increased by 0.8% YoY at AER and declined by 0.9% at CER, protected by OPEX savings, while still investing for growth.
Reported Operating Profit increased by 19.3% YoY at AER, also reflecting a ...
|
|
|
|
|
13.05.26 - 08:33
|
Inventiva to Present Abstracts at the EASL Congress 2026 (GlobeNewswire EN)
|
|
|
Daix (France), New York City (New York, United States), May 13, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the presentation of two abstracts at the upcoming annual congress of the European Association for the Study of the Liver, EASL Congress 2026, to be held from May 27 to 30, 2026 in Barcelona....
|
|
|
|
|
13.05.26 - 08:30
|
MEDP Investors Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit (PR Newswire)
|
|
|
NEW YORK, May 13, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the "Class Period"), of the important June 8, 2026 lead......
|
|
|
|
|
|
|
13.05.26 - 08:13
|
Carl Zeiss Meditec Underweight (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat das Kursziel für Carl Zeiss Meditec von 22,40 auf 21,70 Euro gesenkt und die Einstufung auf "Underweight" belassen. Analyst David Adlington sieht kurz- und mittelfristig enorme Korrekturrisiken für ......
|
|
|
13.05.26 - 08:13
|
Carl Zeiss Meditec Equal Weight (DPA-AFX)
|
|
|
LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Carl Zeiss Meditec von 30 auf 28 Euro gesenkt, aber die Einstufung auf "Equal Weight" belassen. Die mittelfristigen Ziele der Jenaer zeugten vom schwachen Geschäftstrend, ......
|
|
|
13.05.26 - 08:09
|
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ten abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27 – 30, 2026 in Barcelona, Spain. The abstracts released today can be found on the EASL website at https://www.easlcongress.eu/....
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
